# Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

> **NCT02044796** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 199 (actual)

## Conditions studied

- Acute Biphenotypic Leukemia
- de Novo Myelodysplastic Syndrome
- Previously Treated Myelodysplastic Syndrome
- Recurrent Adult Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Cytarabine
- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mitoxantrone Hydrochloride

## Key facts

- **NCT ID:** NCT02044796
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-23
- **Primary completion:** 2018-03-09
- **Final completion:** 2018-04-16
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2020-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02044796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02044796, "Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02044796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*